Quick Facts
FONT-SIZE Plus   Neg
Share SHARE

Dr Pepper Snapple Group Q1 Profit Down; Reaffirms FY12 Outlook - Quick Facts

RELATED NEWS
Trade DPS now with 

Dr Pepper Snapple Group Inc. (DPS: Quote) reported that its first quarter net income declined to $102 million, from $114 million in the same quarter last year. Earnings per share were $0.48 compared to $0.50 in the prior year period.

Excluding $0.02 per share of unrealized commodity mark-to-market gains, Core Earnings per share were $0.46 compared to $0.50 in the prior period.Analysts polled by Thomson Reuters expected the company to report earnings of $0.48 per share for the quarter. Analysts' estimates typically exclude special items.

Revenues for the quarter rose to $1.36 billion from $1.33 billion in the prior year quarter. Ten analysts had consensus revenue estimate of $1.36 billion for the quarter.

The company continues to expect full year 2012 reported net sales growth near the low end of its long-term 3% to 5% range and Core earnings per share to be in the $2.90 to $2.98 range. Analysts expect the company to report earnings of $2.93 per share on revenues of $6.06 billion for fiscal 2012.

Click here to receive FREE breaking news email alerts for Dr. Pepper Snapple Group, Inc. and others in your portfolio

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Proctor and Gamble (PG) has sold two of its soap brands to European consumer products giant Unilever (UN). Cincinnati-based P&G says the sale includes the global Camay brand, the Zest brand outside of North America and its Talisman manufacturing plant in Mexico. The plant employs approximately... Dish Network is no longer carrying Fox News in yet another dispute for the television provider. Fox News, which changed the face of cable news with its ardent advocacy of conservative issues, went dark Sunday, replaced on Dish by The Blaze, Glen Beck's new right-leaning channel. Fox Business channel... Swiss drug maker Roche Holding said a late-stage trial of its breast cancer drug Kadcyla did not provide superior results compared with an existing therapy.
comments powered by Disqus
FREE Newsletters, Analysis & Alerts

 

Stay informed with our FREE daily Newsletters and real-time breaking News Alerts. Sign up to receive the latest information on business news, health, technology, biotech, market analysis, currency trading and more.